What question did this study set out to answer?

To evaluate the efficacy and safety of twice-daily tacrolimus ophthalmic suspension 0.1% compared with placebo in patients with severe allergic conjunctivitis unresponsive to standard topical therapies.

March 22, 2010Journal of Ocular Pharmacology and TherapeuticsOpen Access

A Randomized, Placebo-Controlled Clinical Trial of Tacrolimus Ophthalmic Suspension 0.1% in Severe Allergic Conjunctivitis

View Full Paper

Ask AI

Bookmark

Authors

YOYuichi OhashiSaiseikai Matsuyama Hospital NENobuyuki EbiharaJuntendo University HFHiroshi FujishimaTsurumi University

Discussion

Member takes

Implication

Randomized double-blind trial demonstrates significant clinical improvement in severe allergic conjunctivitis refractory to standard therapies, indicating its value when steroids fail.

Key Points

To evaluate the efficacy and safety of twice-daily tacrolimus ophthalmic suspension 0.1% compared with placebo in patients with severe allergic conjunctivitis unresponsive to standard topical therapies.
Multicenter, randomized, double-masked, placebo-controlled trial including 56 patients with severe allergic conjunctivitis refractory to topical antiallergic agents and corticosteroids.
Patients received either topical tacrolimus 0.1% or placebo twice daily for 4 weeks.
Endpoints included change in total objective sign score across the conjunctiva, limbus, and cornea, as well as subjective symptoms evaluated via visual analog scale (VAS).
Mean change from baseline in total objective sign score was significantly greater in the tacrolimus group (-5.6 ± 5.1) compared to the placebo group (-0.1 ± 4.5; P < 0.001).
Tacrolimus significantly improved giant papillae (P = 0.001) and corneal involvement (P = 0.005), as well as five subjective symptoms: itching, discharge, hyperemia, lacrimation, and foreign body sensation.
The primary treatment-related adverse event in the tacrolimus group was mild ocular irritation upon instillation, which was well-tolerated.

Cite This Study

Ohashi et al. (2010) studied this question.

synapsesocial.com/papers/6a8b976a06ce16d944b1f7ae https://doi.org/10.1089/jop.2009.0087

View Full Paper

Ask AI

Bookmark

Implication

Randomized double-blind trial demonstrates significant clinical improvement in severe allergic conjunctivitis refractory to standard therapies, indicating its value when steroids fail.

A Randomized, Placebo-Controlled Clinical Trial of Tacrolimus Ophthalmic Suspension 0.1% in Severe Allergic Conjunctivitis

Discussion

Member takes

Implication

Key Points

Cite This Study

A Randomized, Placebo-Controlled Clinical Trial of Tacrolimus Ophthalmic Suspension 0.1% in Severe Allergic Conjunctivitis

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider